Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase II clinical trial of its adeno-associated virus (AAV) therapy AB-1002 targeting congestive heart failure (CHF). This placebo-controlled study aims to assess the safety and efficacy of intracoronary infusion in 90 to 150 adults with non-ischemic cardiomyopathy.
The trial will feature a 52-week safety assessment period, with the primary endpoint focusing on a composite of several clinically meaningful outcomes. Participants will also undergo a long-term follow-up spanning four years. Bayer estimates that approximately 26 million individuals worldwide are affected by CHF.- Flcube.com
